TACR1 and hepatoblastoma: A recent study has identified Aprepitant, one of the NK-1R antagonists, as an efficient inhibitor of hepatoblastoma tumor growth by decreasing β-catenin levels and downregulating the Wnt target genes AXIN2 and LGR5 (88).